<p>COMPASS Pathways（納斯達克代碼：CMPS - 獲取免費報告）於週四發佈了季度財報。公司報告本季度每股收益為（$0.38），低於分析師一致預期的（$0.37），差距為（$0.01），據 Zacks 報道。</p>
<p>獲取 <strong>COMPASS Pathways</strong> 警報：</p>
<h2>COMPASS Pathways 股價下跌 0.2%</h2>
<p>週五午盤交易中，納斯達克：CMPS 的股票下跌了 $0.01，報 $4.34。該股票交易量為 2,524,177 股，而其平均交易量為 2,277,808 股。該公司的市值為 $4.0605 億，市盈率為 -2.36，貝塔值為 2.16。公司的債務與股本比率為 0.11，速動比率為 10.18，流動比率為 10.18。該業務的 50 日移動平均價格為 $3.99，200 日移動平均價格為 $3.80。COMPASS Pathways 的 12 個月低點為 $2.25，12 個月高點為 $8.54。</p>
<h2>分析師設定新目標價</h2>
<p>CMPS 一直是幾份研究分析報告的主題。Evercore ISI 在 6 月 23 日的研究報告中重申了 “持平” 評級，並將 COMPASS Pathways 的目標價下調至 $6.00（之前為 $11.00）。HC Wainwright 在 7 月 15 日的研究報告中重申了 “買入” 評級，並將 COMPASS Pathways 的目標價設定為 $45.00。Canaccord Genuity Group 在週五的研究報告中重申了 “買入” 評級，並將 COMPASS Pathways 的目標價設定為 $15.00。最後，Cantor Fitzgerald 在 5 月 27 日的研究報告中重申了 “增持” 評級，並將 COMPASS Pathways 的目標價設定為 $12.00。一位分析師對該股票給予了持有評級，六位分析師給予了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 $17.00。</p>
<p><strong>閲讀我們關於 CMPS 的最新研究報告</strong></p>
<h2>COMPASS Pathways 的機構交易</h2>
<p>一家機構投資者最近增加了在 COMPASS Pathways 股票中的持倉。根據該公司在最近向證券交易委員會提交的 13F 表格，皇家加拿大銀行在第一季度將其在 COMPASS Pathways PLC 贊助的 ADR（納斯達克：CMPS - 免費報告）中的持倉提高了 49.8%。該基金在此期間購買了額外的 29,733 股後，持有該公司 89,446 股股票。根據其最近向證券交易委員會提交的文件，皇家加拿大銀行持有的 COMPASS Pathways 股票約佔 0.10%，價值 $256,000。機構投資者和對沖基金持有該公司 46.19% 的股票。</p>
<h2>COMPASS Pathways 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>COMPASS Pathways plc 在英國和美國運營，作為一家心理健康護理公司。它開發的 COMP360 是一種正在進行 III 期臨牀試驗的迷幻蘑菇治療，用於治療難治性抑鬱症；並且正在進行 II 期臨牀試驗，用於治療創傷後應激障礙和神經性厭食症。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而非 COMPASS Pathways</li>
<li>如何投資科技股及值得考慮的頂級科技股</li>
<li>比特幣與股息：這三隻 ETF 的贏家組合</li>
<li>投資石油股的方式與原因</li>
<li>PG&amp;E 是 AI 的投資機會嗎？為何期權交易者在大舉押注</li>
<li>如何在購買前評估一隻股票</li>
<li>MarketBeat 週報 – 07/28 - 08/01</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 COMPASS Pathways 嗎？</h2>
<p>在考慮 COMPASS Pathways 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 COMPASS Pathways 並不在名單上。</p>
<p>儘管 COMPASS Pathways 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CMPS

<p>COMPASS Pathways（納斯達克代碼：CMPS）報告季度每股收益為（$0.38），低於預期$0.01。該股下跌 0.2%，報$4.34，市值為 4.0605 億美元。分析師對其評級不一，普遍目標價為$17.00。機構投資者持有該公司 46.19% 的股份，該公司專注於用於心理健康狀況的迷幻蘑菇治療。儘管評級為適度買入，COMPASS Pathways 並不是分析師推薦的頂級股票之一</p>

<p>COMPASS Pathways (NASDAQ:CMPS - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01), Zacks reports.</p>
<div class="lb-trans"><p>COMPASS Pathways（納斯達克代碼：CMPS - 獲取免費報告）於週四發佈了季度財報。公司報告本季度每股收益為（$0.38），低於分析師一致預期的（$0.37），差距為（$0.01），據 Zacks 報道。</p>
</div><p>Get <strong>COMPASS Pathways</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>COMPASS Pathways</strong> 警報：</p>
</div><h2>COMPASS Pathways Trading Down 0.2%</h2>
<div class="lb-trans"><h2>COMPASS Pathways 股價下跌 0.2%</h2>
</div><p>Shares of NASDAQ:CMPS traded down $0.01 during midday trading on Friday, hitting $4.34. 2,524,177 shares of the stock were exchanged, compared to its average volume of 2,277,808. The stock has a market capitalization of $406.05 million, a price-to-earnings ratio of -2.36 and a beta of 2.16. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.18 and a current ratio of 10.18. The business's 50-day moving average price is $3.99 and its 200 day moving average price is $3.80. COMPASS Pathways has a 12 month low of $2.25 and a 12 month high of $8.54.</p>
<div class="lb-trans"><p>週五午盤交易中，納斯達克：CMPS 的股票下跌了 $0.01，報 $4.34。該股票交易量為 2,524,177 股，而其平均交易量為 2,277,808 股。該公司的市值為 $4.0605 億，市盈率為 -2.36，貝塔值為 2.16。公司的債務與股本比率為 0.11，速動比率為 10.18，流動比率為 10.18。該業務的 50 日移動平均價格為 $3.99，200 日移動平均價格為 $3.80。COMPASS Pathways 的 12 個月低點為 $2.25，12 個月高點為 $8.54。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>CMPS has been the topic of several research analyst reports. Evercore ISI reaffirmed an &#34;in-line&#34; rating and issued a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday, July 15th. Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a $15.00 target price on shares of COMPASS Pathways in a research report on Friday. Finally, Cantor Fitzgerald reiterated an &#34;overweight&#34; rating and issued a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $17.00.</p>
<div class="lb-trans"><p>CMPS 一直是幾份研究分析報告的主題。Evercore ISI 在 6 月 23 日的研究報告中重申了 “持平” 評級，並將 COMPASS Pathways 的目標價下調至 $6.00（之前為 $11.00）。HC Wainwright 在 7 月 15 日的研究報告中重申了 “買入” 評級，並將 COMPASS Pathways 的目標價設定為 $45.00。Canaccord Genuity Group 在週五的研究報告中重申了 “買入” 評級，並將 COMPASS Pathways 的目標價設定為 $15.00。最後，Cantor Fitzgerald 在 5 月 27 日的研究報告中重申了 “增持” 評級，並將 COMPASS Pathways 的目標價設定為 $12.00。一位分析師對該股票給予了持有評級，六位分析師給予了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 $17.00。</p>
</div><p><strong>Read Our Latest Research Report on CMPS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CMPS 的最新研究報告</strong></p>
</div><h2>Institutional Trading of COMPASS Pathways</h2>
<div class="lb-trans"><h2>COMPASS Pathways 的機構交易</h2>
</div><p>An institutional investor recently raised its position in COMPASS Pathways stock. Royal Bank of Canada lifted its position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 49.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,446 shares of the company's stock after purchasing an additional 29,733 shares during the period. Royal Bank of Canada owned about 0.10% of COMPASS Pathways worth $256,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 46.19% of the company's stock.</p>
<div class="lb-trans"><p>一家機構投資者最近增加了在 COMPASS Pathways 股票中的持倉。根據該公司在最近向證券交易委員會提交的 13F 表格，皇家加拿大銀行在第一季度將其在 COMPASS Pathways PLC 贊助的 ADR（納斯達克：CMPS - 免費報告）中的持倉提高了 49.8%。該基金在此期間購買了額外的 29,733 股後，持有該公司 89,446 股股票。根據其最近向證券交易委員會提交的文件，皇家加拿大銀行持有的 COMPASS Pathways 股票約佔 0.10%，價值 $256,000。機構投資者和對沖基金持有該公司 46.19% 的股票。</p>
</div><h2>COMPASS Pathways Company Profile</h2>
<div class="lb-trans"><h2>COMPASS Pathways 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.</p>
<div class="lb-trans"><p>COMPASS Pathways plc 在英國和美國運營，作為一家心理健康護理公司。它開發的 COMP360 是一種正在進行 III 期臨牀試驗的迷幻蘑菇治療，用於治療難治性抑鬱症；並且正在進行 II 期臨牀試驗，用於治療創傷後應激障礙和神經性厭食症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than COMPASS Pathways</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Bitcoin and Dividends: A Winning Combo in These 3 ETFs</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Is PG&amp;E an AI Power Play? Why Options Traders Are Betting Big</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>MarketBeat Week in Review – 07/28 - 08/01</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 COMPASS Pathways</li>
<li>如何投資科技股及值得考慮的頂級科技股</li>
<li>比特幣與股息：這三隻 ETF 的贏家組合</li>
<li>投資石油股的方式與原因</li>
<li>PG&amp;E 是 AI 的投資機會嗎？為何期權交易者在大舉押注</li>
<li>如何在購買前評估一隻股票</li>
<li>MarketBeat 週報 – 07/28 - 08/01</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CMPS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in COMPASS Pathways Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 COMPASS Pathways 嗎？</h2>
</div><p>Before you consider COMPASS Pathways, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 COMPASS Pathways 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 COMPASS Pathways 並不在名單上。</p>
</div><p>While COMPASS Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 COMPASS Pathways 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Compass Pathways（納斯達克代碼：CMPS）公佈了財報結果，每股收益比預期低 0.01 美元